ClinicalTrials.gg
Active, not recruitingNCT06607497BRILLIANTUpdated May 12, 2026

Better Risk Perception Via Patient Similarity to Control Hyperglycemia and Sustained by Telemonitoring

An interventional study of Intervention using an AI enabled risk communication tool (PERDICT.AI) and Telemonitoring with Primary Tech Enhanced Care (PTEC-DM) in Diabetes Mellitus, Type 2, sponsored by SingHealth Polyclinics. Active, not recruiting at 1 site in Singapore. Open to participants aged 36 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by SingHealth Polyclinics · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
36 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore — 12 open to participants now, 20 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Singapore.

Enrollment
29th of 98
360 · median 121
Started
2024
with 4 others
No phase
50 of 112
8 open now
Primary completion
2026-12
later than 13 of 19 live
Registered
102nd of 112
by date
Lead sponsor
4 of 112
SingHealth Polyclinics

Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore, this one is the 29th largest by enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2024, is one of 50 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 102nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

12 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 36 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Diabetes Mellitus, Type 2 with a site in Singapore, or all of them as a file.
02

Study summary

Background: Diabetes significantly raises the likelihood of complications, thereby increasing the risk of diabetes-related mortality, particularly due to vascular complications. It is vital to address this rising trend of mortality, by enhancing awareness of diabetes complications to improve risk perception and ultimately reduce mortality rates. Managing diabetes effectively requires interventions addressing both risk communication and monitoring, helping patients better understand and make informed decisions about their health.

Objectives: The primary aim is to evaluate and compare the effectiveness of combined risk communication session using an AI module (PERDICT.AI) and home-based diabetes monitoring (PTEC-DM) versus a standalone risk communication session in improving health outcomes (risk perception, medication adherence, self-care activities and glycaemic control) among poorly controlled diabetes patients. Secondary aims are to explore participants' views and experiences of risk communication session using PERDICT.AI, PTEC-DM and usual care and clinician' views on utility of the new approach to improve risk perception.

Methods: A mixed-method study design will be employed to conduct a multi-arm randomized controlled trial across four of the SingHealth Polyclinics cluster (Pasir Ris, Eunos, Sengkang, Tampines North). Patient participants will be randomly allocated in a 1:1:1 ratio to one of the three arms. Arm 1 will receive risk communication session using PERDICT.AI and home-based diabetes monitoring using PTEC-DM alongside usual care. Arm 2 participants will undergo a standalone risk communication session using PERDICT.AI with usual care while arm 3 will serve as the control group with usual care. A total of 360 (120 in each group) participants will be enrolled by simple randomization. Eligible patient must be of age between 36 and 65 years with HbA1c >8.0% within the last 6 months.

Significance of the study: Findings from the study may add evidence to the scientific knowledge of using these approaches to improve risk perception and recommend development of similar interventions.

Read the detailed description

Diabetes has emerged as a significant public health concern globally, and Singapore is no exception. As of 2022, 8.5% of the adults in Singapore is affected by diabetes and the number is expected to reach 1 million by 2050, making it imperative to address the associated challenges. The economic implications of diabetes extend beyond healthcare costs, impacting productivity and quality of life. The total cost among the working-age population with diabetes - direct and indirect costs included - is expected to rise from USD 787 million (USD 5,646 per person) in 2010 to USD 1,867 million in 2050 (USD 7,791 per person).

In addition, diabetes poses a substantial risk of complications that can adversely impact various organ systems. Complications such as cardiovascular diseases, neuropathy, and retinopathy pose severe threats to the health of individuals with poorly managed diabetes. A study on global trend of diabetes mortality revealed a concerning global increase in diabetes-related mortality, particularly due to vascular complications, posing a significant challenge to diabetes management. To address the rising trends of mortality, it is crucial to enhance awareness of diabetes complications to improve risk perception and ultimately reduce mortality rates.

Perceived risk of diabetes complications can impact patient behavior, influencing adherence to treatment plans and lifestyle changes. Individuals with a higher risk perception may be more likely to engage in proactive management, leading to better health outcomes and potentially reducing mortality rates associated with diabetes complications. On the other hand, individuals with poorer risk perception may neglect necessary precautions, leading to suboptimal disease management and an increased likelihood of complications, potentially impacting mortality rates.

A systematic review on risk perceptions of diabetes complications highlights a concerning lack of awareness regarding the risk of diabetes related complications among individuals with type 2 diabetes mellitus (T2DM). Similarly, research studies on diabetes complications risk awareness, particularly in Singapore, revealed knowledge gaps among adults. Despite the significant impact on quality of life, later-stage T2DM and its complications were perceived as slowly progressing and not immediately life-threatening. Hence, for poorly controlled diabetes patients, effective communication regarding the risks of complications is paramount.

Weaver et al defined risk communication as "the effective and accurate exchange of information about health risks and hazards" so as to "advance risk awareness and understanding and promote health-protective behaviors". Enhancing risk communication not only promotes informed decision-making but also advances early intervention and preventive measures. Furthermore, Hashim J et al emphasized the importance of considering social and cultural factors in the development of effective interventions among adults with elevated risk perception yet do not engage in preventive actions. The study also suggested that diverse perspectives concerning the benefits and weaknesses related to preventive measures can impact the long-term sustainability of these behaviors.

Risk communication interventions have been developed for patients with T2DM to improve their risk perceptions and health actions. These interventional studies explore different methods to communicate diabetes complication risks to those with T2DM. interventions include range of innovative risk communication methods like visual aids, general nudges, digital tool for personalized risk information and family support through WeChat. While such interventions contribute to valuable insights, there are some limitations with these tools like limited long-term impact, technology adoption challenges. Addressing these drawbacks with an integrated approach could enhance the robustness and applicability of the findings in diverse healthcare settings.

PERDICT.AI based counselling

An AI-enabled similarity-based model, named PERDICT.AI (Personalised Diabetes Counselling Tool using Artificial Intelligence) was developed by a team of primary care physicians and computer scientists in Singapore to help physicians communicate risks to patients with diabetes mellitus. The tool ranks a patients' HbA1c levels with similar patients (or peers) from a de-identified database, showing how prevalent diabetes complications are based on HbA1c severity. This is referred to as "peer-comparison" and the tool underwent revisions following feedback from primary care physicians to enhance its usefulness in risk communication.

Based on Health Belief Model (HBM), a risk communication intervention, was developed for Primary care Physicians (PCPs) to counsel patients with T2DM on their glycemic control and the complications that could arise, and to recommend ways to improve glycemic control and prevent complications (or further complications). This will be supported by information from PERDICT.AI.

Risk communication using PERDICT.AI dynamically communicates an individual's glycaemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.

Diabetes management often requires consistent encouragement and guidance, which a static risk communication tool may not deliver. In addition, passive receipt of information might not motivate patients to actively take part in diabetes management. Such lack of engagement could lead to reduced adherence to recommended strategies, limiting the tool's overall impact. This is evident from the @RISK study, where the improved risk perception observed initially at 2 weeks dissipated by the 12th week, highlighting a temporal limitation in sustaining positive outcomes. Although participants in the intervention arm reported higher satisfaction with risk communication, this did not translate into sustained improvements. This underscores the need for an integrated approach to sustain positive outcomes beyond short-term.

Integration with telemonitoring system

Sustaining improved risk perception over an extended period can be achieved through telemonitoring. By utilizing telemonitoring technology, healthcare providers can maintain a consistent connection with patients, offering real-time insights into their health status. Additionally, telemonitoring facilitates continuous education and support, thereby contributing to the long-term sustainability of improved risk perception and can significantly enhance diabetes management and prevent complications.

The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.

The integration of PTEC-DM with the risk communication using PERDICT.AI capitalizes on the strengths of human interaction and adaptability, contributing to a more holistic and patient-centred diabetes management approach. Such combined approach addresses both monitoring and guidance, contributing to enhanced patient understanding and informed decision-making. Hence this study is designed with the following objectives, adopting a multi-site, multi-arm randomized controlled trial design.

Objectives

Primary objective:

i. To assess the effectiveness of the risk communication using an AI enabled tool (PERDICT.AI) in improving risk perception score, quality of life and health outcomes (medication adherence and selfcare activities and glycemic control) among poorly controlled diabetes patients ii. To determine the effectiveness of a combination of risk communication session using PERDICT.AI and telemonitoring (PTEC-DM) in improving risk perception, quality of life and health outcomes

Secondary objectives:

iii. To compare the impact of the two approaches in improving risk perception, quality of life and health outcomes among poorly controlled diabetes patients iv. To assess the cost-effectiveness of the advanced care by comparing the incremental costs and health outcomes v. To explore participants' views and experiences of risk communication session using PERDICT.AI, PTEC-DM and usual care vi. To explore clinician' views on utility of the new approach to improve risk perception

Hypothesis:

  • There will be improvement in patients' risk perception score and health outcomes (glycemic control and self-care activities) after the intervention.

Materials and methods

Study setting The study will be conducted at 4 polyclinics from a primary care clinic cluster taking care of more than 200,000 residents with diabetes in the Eastern region of Singapore.

Study design Sequential explanatory mixed-method study

Quantitative: Multi-arm randomized controlled trial (RCT) at four polyclinics which includes SingHealth Polyclinics at Pasir Ris, Tampines North, Eunos and Sengkang.

Qualitative: In-depth interview among the study participants' and clinician, who are integral part of the study team delivering interventions.

Quantitative: Multi-arm RCT This RCT involves three arms, incorporating a combination of interventions and standard care, as outlined below.

Arm 1: Advanced care with risk communication using an AI enabled tool (PERDICT.AI) + home-based monitoring using PTEC DM (main intervention arm) Arm 2: Usual care + risk communication using an AI enabled tool (PERDICT.AI) Arm 3: Usual care All groups will also receive a diabetes pamphlet.

Randomization Patient participants from each study site will be randomly allocated in a 1:1:1 ratio to one of the above-mentioned arms in an open-label fashion, using computer-generated random numbers for simple randomization of subjects. The nature of the intervention makes impossible to blind patients and research team to participant allocation. The randomization sequence is written and kept in an opaque sealed envelope, which will be labelled with a serial number. The study team will open the sealed envelope once the patient has consented to participate and then will be assigned to the study arms accordingly. All participants will receive a diabetes pamphlet ('Pamphlet - Taking Control of Diabetes').

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
36 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus on follow-up at the study site for at least 12 months
  • Age 36 to 65 years
  • At least one reading ≥ 8.0% within the last 6 months
  • Able to read and speak English

Exclusion criteria

Exclusion Criteria:

  • Not a Singapore citizen or permanent resident
  • Pregnant
  • End-stage kidney disease or on renal replacement therapy
  • Known terminal illness
  • Visual and/or hearing impairment
  • Cognitive impairment or mental illness
  • Unable to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Arm 1

    In arm 1, participants will attend the risk communication session utilizing AI module (PERDICT.AI) delivered by the study team integrated with Home-based Diabetes Monitoring (PTEC-DM) providing personalized guidance through teleconsultation in addition to usual care. Screen activity of PERDICT.AI will be recorded using a screen capture software. The entire session will be audio recorded.

    Other: Intervention using an AI enabled risk communication tool (PERDICT.AI) · Other: Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)

  • Experimental
    Arm 2

    In arm 2, participants will attend the risk communication session utilising AI module (PERDICT.AI) without PTEC-DM. Screen activity of PERDICT.AI will be recorded using a screen capture software. The entire session will be audio recorded.

    Other: Intervention using an AI enabled risk communication tool (PERDICT.AI)

  • No intervention
    Arm 3

    Arm 3 will be the active control group, receiving only standard care

Interventions

  • OtherIntervention using an AI enabled risk communication tool (PERDICT.AI)

    Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.

  • OtherTelemonitoring with Primary Tech Enhanced Care (PTEC-DM)

    The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.

06

What researchers measure

Primary outcomes

  1. Risk Perception Survey-Diabetes Mellitus (RPS-DM)

    The RPS-DM consists of 31 questions. The first section assesses risk knowledge (5 items scored on 3-point scale with 1 point for each correct answer; higher score indicates greater knowledge of the risk of getting diabetes complications). The remaining 26 items comprise 5 subscales which can be described as: perceived personal control (4 items scored on 4-point scale); worry (2 items scored on 4-point scale), optimistic bias (2 items scored on 4-point scale); personal disease risk (9 items scored on a 4-point scale; indicates degree of own perceived risk of getting 9 diseases or conditions, plus additional question about whether they have ever had the condition, scored yes/no with 1 point added for yes response); and environmental risk (9 items scored on a 4-point scale). The composite risk perception is the average of the 26 items in the main questionnaire; higher scores indicate greater comparative perceived risk.

    Time frame: through study completion, an average of 12 to 16 months

  2. Health related Quality of life

    Change in the scores using EQ-5D-5L questionnaire; The EQ-5D-5L tool comprises five dimensions, each describing a different aspect of health: mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. Each dimension has five response levels (no problems, slight problems, moderate problems, severe problems, unable to/ extreme problems). The proportion of patients reporting each level of problem on each dimension of the EQ-5D will be determined through study completion and compared. EQ VAS (Visual Analogue Scale) provides a quantitative measure of the patient's perception of their overall health. The EQ VAS records the respondent's overall current health on a vertical scale (0-100), where the endpoints are labelled '0-The worst health you can imagine' and '100-The best health you can imagine'.

    Time frame: through study completion, an average of 12 to 16 months

  3. Medication adherence

    Change in the scores using five item Medication Adherence Report Scale (MARS-5); MARS-5 score was calculated by summing the numeric score (range 1-5) from each question for out of 25 (range 5-25). A higher score indicates better adherence.

    Time frame: through study completion, an average of 12 to 16 months

  4. Summary of Diabetes Self-care Activities (SDSCA) questionnaire

    SDSCA questionnaire collects data on general diet, specific diet, exercise, blood-glucose testing, foot care, and smoking, using an 8-point Likert-type scale (0-7), which represents the number of days per week when the given self-care activity was performed. Scores are calculated separately for each item and the level of adherence is indicated by the mean score for each dimension.

    Time frame: through study completion, an average of 12 to 16 months

  5. Iowa-Netherlands Comparison Orientation Measure (INCOM)

    The INCOM is an 11-item measure of one's tendency to make social comparisons. The scale includes such items as: "I always like to know what others in a similar situation would do." Response choices range from 1 (disagree strongly) to 5 (agree strongly). Higher scores indicate more of a tendency to socially compare.

    Time frame: baseline enrolment

Secondary outcomes

  1. Cost-effectiveness analysis

    Unit costs for consultation, laboratory, hospitalization, and pharmacy services, as well as the expenses for home-based monitoring (including a Bluetooth-enabled glucometer, test strips, lancets, and a blood pressure monitor), will be estimated to assess the cost-effectiveness of the advanced care by comparing the incremental costs and health outcomes

    Time frame: through study completion, an average of 12 to 16 months

  2. Views and experiences of risk communication session using PERDICT.AI, PTEC-DM and usual care

    in-depth interview with the participants till point of data saturation

    Time frame: 24-48 weeks

  3. Exploring clinician' views on utility of combined intervention to improve risk perception

    in-depth interview with the study team doctors till point of data saturation

    Time frame: 24-48 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Png ME, Yoong J, Phan TP, Wee HL. Current and future economic burden of diabetes among working-age adults in Asia: conservative estimates for Singapore from 2010-2050. BMC Public Health. 2016 Feb 16;16:153. doi: 10.1186/s12889-016-2827-1. PubMed 26880337 ↗
  • Ling W, Huang Y, Huang YM, Fan RR, Sui Y, Zhao HL. Global trend of diabetes mortality attributed to vascular complications, 2000-2016. Cardiovasc Diabetol. 2020 Oct 20;19(1):182. doi: 10.1186/s12933-020-01159-5. PubMed 33081808 ↗
  • Nie R, Han Y, Xu J, Huang Q, Mao J. Illness perception, risk perception and health promotion self-care behaviors among Chinese patient with type 2 diabetes: A cross-sectional survey. Appl Nurs Res. 2018 Feb;39:89-96. doi: 10.1016/j.apnr.2017.11.010. Epub 2017 Nov 7. PubMed 29422183 ↗
  • Mousavizadeh SN, Ashktorab T, Ahmadi F, Zandi M. From Negligence to Perception of Complexities in Adherence to Treatment Process in People with Diabetes: A Grounded Theory Study. Iran J Med Sci. 2018 Mar;43(2):150-157. PubMed 29749983 ↗
  • Rouyard T, Kent S, Baskerville R, Leal J, Gray A. Perceptions of risks for diabetes-related complications in Type 2 diabetes populations: a systematic review. Diabet Med. 2017 Apr;34(4):467-477. doi: 10.1111/dme.13285. Epub 2016 Nov 29. PubMed 27864886 ↗
  • Wee HL, Ho HK, Li SC. Public awareness of diabetes mellitus in Singapore. Singapore Med J. 2002 Mar;43(3):128-34. PubMed 12005338 ↗
  • Tham KY, Ong JJ, Tan DK, How KY. How much do diabetic patients know about diabetes mellitus and its complications? Ann Acad Med Singap. 2004 Jul;33(4):503-9. PubMed 15329765 ↗
  • Hashim J, Smith HE, Tai ES, Yi H. Lay perceptions of diabetes mellitus and prevention costs and benefits among adults undiagnosed with the condition in Singapore: a qualitative study. BMC Public Health. 2022 Aug 20;22(1):1582. doi: 10.1186/s12889-022-14020-z. PubMed 35987615 ↗
  • Welschen LM, Bot SD, Dekker JM, Timmermans DR, van der Weijden T, Nijpels G. The @RISK Study: Risk communication for patients with type 2 diabetes: design of a randomised controlled trial. BMC Public Health. 2010 Aug 5;10:457. doi: 10.1186/1471-2458-10-457. PubMed 20687924 ↗
  • Welschen LM, Bot SD, Kostense PJ, Dekker JM, Timmermans DR, van der Weijden T, Nijpels G. Effects of cardiovascular disease risk communication for patients with type 2 diabetes on risk perception in a randomized controlled trial: the @RISK study. Diabetes Care. 2012 Dec;35(12):2485-92. doi: 10.2337/dc11-2130. Epub 2012 Aug 24. PubMed 22923669 ↗
  • Rouyard T, Leal J, Baskerville R, Velardo C, Salvi D, Gray A. Nudging people with Type 2 diabetes towards better self-management through personalized risk communication: A pilot randomized controlled trial in primary care. Endocrinol Diabetes Metab. 2018 Jun 22;1(3):e00022. doi: 10.1002/edm2.22. eCollection 2018 Jul. PubMed 30815556 ↗
  • Rouyard T, Leal J, Salvi D, Baskerville R, Velardo C, Gray A. An Intuitive Risk Communication Tool to Enhance Patient-Provider Partnership in Diabetes Consultation. J Diabetes Sci Technol. 2022 Jul;16(4):988-994. doi: 10.1177/1932296821995800. Epub 2021 Mar 3. PubMed 33655766 ↗
  • Mao L, Lu J, Zhang Q, Zhao Y, Chen G, Sun M, Chang F, Li X. Family-based intervention for patients with type 2 diabetes via WeChat in China: protocol for a randomized controlled trial. BMC Public Health. 2019 Apr 5;19(1):381. doi: 10.1186/s12889-019-6702-8. PubMed 30953483 ↗
  • Feng Y, Zhao Y, Mao L, Gu M, Yuan H, Lu J, Zhang Q, Zhao Q, Li X. The Effectiveness of an eHealth Family-Based Intervention Program in Patients With Uncontrolled Type 2 Diabetes Mellitus (T2DM) in the Community Via WeChat: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2023 Mar 20;11:e40420. doi: 10.2196/40420. PubMed 36939825 ↗
  • Fang HSA, Tan NC, Tan WY, Oei RW, Lee ML, Hsu W. Patient similarity analytics for explainable clinical risk prediction. BMC Med Inform Decis Mak. 2021 Jul 1;21(1):207. doi: 10.1186/s12911-021-01566-y. PubMed 34210320 ↗
  • Oei RW, Fang HSA, Tan WY, Hsu W, Lee ML, Tan NC. Using Domain Knowledge and Data-Driven Insights for Patient Similarity Analytics. J Pers Med. 2021 Jul 22;11(8):699. doi: 10.3390/jpm11080699. PubMed 34442343 ↗
  • Andres E, Meyer L, Zulfiqar AA, Hajjam M, Talha S, Bahougne T, Erve S, Hajjam J, Doucet J, Jeandidier N, Hajjam El Hassani A. Telemonitoring in diabetes: evolution of concepts and technologies, with a focus on results of the more recent studies. J Med Life. 2019 Jul-Sep;12(3):203-214. doi: 10.25122/jml-2019-0006. PubMed 31666818 ↗
  • Lim DYZ, Chia SY, Abdul Kadir H, Mohamed Salim NN, Bee YM. Establishment of the SingHealth Diabetes Registry. Clin Epidemiol. 2021 Mar 16;13:215-223. doi: 10.2147/CLEP.S300663. eCollection 2021. PubMed 33762850 ↗
  • Gibbons FX, Buunk BP. Individual differences in social comparison: development of a scale of social comparison orientation. J Pers Soc Psychol. 1999 Jan;76(1):129-42. doi: 10.1037//0022-3514.76.1.129. PubMed 9972558 ↗
  • Walker EA, Caban A, Schechter CB, Basch CE, Blanco E, DeWitt T, Kalten MR, Mera MS, Mojica G. Measuring comparative risk perceptions in an urban minority population: the risk perception survey for diabetes. Diabetes Educ. 2007 Jan-Feb;33(1):103-10. doi: 10.1177/0145721706298198. PubMed 17272796 ↗
  • Seng JJB, Kwan YH, Fong W, Phang JK, Lui NL, Thumboo J, Leung YY. Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore. Eur J Rheumatol. 2020 Apr;7(2):71-78. doi: 10.5152/eurjrheum.2020.19043. Epub 2020 Apr 1. PubMed 32644927 ↗
  • Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288. doi: 10.1111/bcp.14193. Epub 2020 May 18. PubMed 31823381 ↗
  • Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000 Jul;23(7):943-50. doi: 10.2337/diacare.23.7.943. PubMed 10895844 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 29 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 23, 2024
StartActual
Jul 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607497
Lead sponsor
SingHealth Polyclinics
Collaborators
AISG Health Grand Challenge
Responsible party
Tan Ngiap Chuan (Principal Investigator, SingHealth Polyclinics) — Principal investigator
First posted
Sep 23, 2024
Start date
Jul 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Ngiap Chuan Tan, MMed
principal investigator · SingHealth Polyclinics

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion